# Can-Fite BioPharma Ltd.: Form 20-F for the period ended Dec 31, 2019

- Company: [Can-Fite BioPharma Ltd.](/companies/canf.md) (CIK 1536196)
- Form: 20-F
- Filed: 2020-03-27
- Accepted by EDGAR: Mar 27, 2020, 16:26 ET
- Period: 2019-12-31
- Accession: 0001213900-20-007682
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1536196/000121390020007682/f20f2019_canfitebiopharma.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1536196/000121390020007682/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 12 months, 2019-01-01 to 2019-12-31 | $11.0m | us-gaap:ResearchAndDevelopmentExpense |
| Shares outstanding | at 2019-12-31 | 120,652,683 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1536196/000121390020007682/f20f2019_canfitebiopharma.htm

Filed Mar 27, 2020.
Source: SEC EDGAR, the filing index for accession 0001213900-20-007682. Last ingested by Listed: Nov 2, 2026, 07:04 ET. No prices; not investment advice.